Lyophilisation: difference between revisions
Diff·revision 24 → 25·23:37, 20 Aug 2025
Difference between revision 24 and revision 25 of Lyophilisation. 9 lines changed; the page grew by 1,596 bytes.
| Revision 24 — 16:54, 29 Jul 2025 CustomsClarke (talk) expand §Freezing 24,779 bytes ±0 | Revision 25 — 23:37, 20 Aug 2025 Chromatokid (talk) add the reconstitution-stability sentence with its storage condition 26,375 bytes +1,596 | ||
|---|---|---|---|
| 144 | Reconstitution time and clarity detect collapse, over-concentration and incipient aggregation. A cake that requires prolonged agitation, or that yields a hazy solution, is a documented indicator of physical instability even when chemical assay is within specification.{{r|wang2000}} | 144 | Reconstitution time and clarity detect collapse, over-concentration and incipient aggregation. A cake that requires prolonged agitation, or that yields a hazy solution, is a documented indicator of physical instability even when chemical assay is within specification.{{r|wang2000}} |
| 145 | 145 | ||
| + | 146 | Headspace composition is set at stoppering. Vials sealed under partial vacuum or under nitrogen exclude oxygen and thereby suppress [[Methionine oxidation|methionine oxidation]] during storage; vials sealed at atmospheric pressure in air do not. Headspace pressure is measurable non-destructively by laser-based headspace analysis, which is also used as a container-closure integrity method under USP <1207>.{{r|usp1207}} | |
| + | 147 | ||
| 146 | == Why lyophilised material tolerates ambient shipping == | 148 | == Why lyophilised material tolerates ambient shipping == |
| 147 | The practical significance of lyophilisation for distribution is that it removes the dominant degradation pathway. Hydrolytic reactions require water and molecular mobility; a dry amorphous glass held below its glass transition temperature provides neither in quantity. Reported consequences are large. Degradation rates for peptides in the dry state are commonly two to three orders of magnitude below rates for the same peptide in solution at the same temperature, and the temperature sensitivity of the residual degradation is correspondingly lower.{{r|chang2009,wang2000}} | 149 | The practical significance of lyophilisation for distribution is that it removes the dominant degradation pathway. Hydrolytic reactions require water and molecular mobility; a dry amorphous glass held below its glass transition temperature provides neither in quantity. Reported consequences are large. Degradation rates for peptides in the dry state are commonly two to three orders of magnitude below rates for the same peptide in solution at the same temperature, and the temperature sensitivity of the residual degradation is correspondingly lower.{{r|chang2009,wang2000}} |
| ⋮ | ⋮ | ||
| 149 | This is the basis for the common practice of shipping lyophilised research peptides at ambient temperature without refrigeration, and for manufacturers' statements that a lyophilised product tolerates transient warming. It is not a licence to disregard temperature entirely. The glass transition temperature of a dry peptide-sucrose matrix may be only 40–70 °C; a parcel left in a vehicle in summer can plausibly approach that range, and above it the matrix devitrifies and mobility rises sharply. Moisture ingress through a compromised seal has the same effect, because water plasticises the glass and lowers its transition temperature by tens of degrees.{{r|chang2009}} | 151 | This is the basis for the common practice of shipping lyophilised research peptides at ambient temperature without refrigeration, and for manufacturers' statements that a lyophilised product tolerates transient warming. It is not a licence to disregard temperature entirely. The glass transition temperature of a dry peptide-sucrose matrix may be only 40–70 °C; a parcel left in a vehicle in summer can plausibly approach that range, and above it the matrix devitrifies and mobility rises sharply. Moisture ingress through a compromised seal has the same effect, because water plasticises the glass and lowers its transition temperature by tens of degrees.{{r|chang2009}} |
| 150 | 152 | ||
| + | 153 | The evidence available for any particular unregulated product is usually nil. A manufacturer's stability programme conducted under [[Cold chain|cold-chain]] and ICH conditions produces data that support a labelled storage statement; material distributed without such a programme carries a storage recommendation that is, at best, an inference from the behaviour of similar compounds.{{r|ich_q1a}} Community-collated observations of material that appeared to perform normally after warm transit exist but are self-reported, unblinded, and without pre-excursion analytical baselines, and cannot establish the absence of degradation.{{r|ppcommunity}} | |
| + | 154 | ||
| 151 | == References == | 155 | == References == |
| 152 | {{reflist}} | 156 | {{reflist}} |
| ⋮ | ⋮ | ||
| 163 | <ref name="usp1207">United States Pharmacopeia, General Chapter <1207>, "Package Integrity Evaluation — Sterile Products". USP–NF, current revision.</ref> | 167 | <ref name="usp1207">United States Pharmacopeia, General Chapter <1207>, "Package Integrity Evaluation — Sterile Products". USP–NF, current revision.</ref> |
| 164 | <ref name="iso8362_5">ISO 8362-5:2016, ''Injection containers and accessories — Part 5: Freeze drying closures for injection vials''. International Organization for Standardization.</ref> | 168 | <ref name="iso8362_5">ISO 8362-5:2016, ''Injection containers and accessories — Part 5: Freeze drying closures for injection vials''. International Organization for Standardization.</ref> |
| + | 169 | <ref name="ich_q1a">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> | |
| + | 170 | <ref name="ppcommunity">PeptidePedia community handling-report tally, 2026 (self-reported, unblinded, no pre-exposure baselines; weak evidence — see [[Project:Sourcing_guidelines]]).</ref> | |
| 165 | 171 | ||
| 166 | == Further reading == | 172 | == Further reading == |
| ⋮ | ⋮ | ||
| 168 | * Franks F. "Freeze-drying of bioproducts: putting principles into practice." ''European Journal of Pharmaceutics and Biopharmaceutics'' 45(3):221–229 (1998). | 174 | * Franks F. "Freeze-drying of bioproducts: putting principles into practice." ''European Journal of Pharmaceutics and Biopharmaceutics'' 45(3):221–229 (1998). |
| 169 | * Pikal MJ. "Freeze-drying of proteins: process, formulation, and stability." ''ACS Symposium Series'' 567:120–133 (1994). | 175 | * Pikal MJ. "Freeze-drying of proteins: process, formulation, and stability." ''ACS Symposium Series'' 567:120–133 (1994). |
| + | 176 | ||
| + | 177 | == External links == | |
| + | 178 | * [https://www.iso.org/ ISO 8362 series (catalogue entry)] — Standards for injection containers, closures and freeze-drying closures. Paywalled; abstracts are public. | |
| 170 | 179 | ||
| 171 | == See also == | 180 | == See also == |